Kodiak Sciences 株価情報 (NASDAQ: KOD)

最新ニュース Kodiak Sciences (NASDAQ:KOD) 株価情報

Kodiak Sciences

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Kodiak Sciences Inc

Eastman Kodak Co

KODAL MINERALS PLC by KODAL MINERALS PLC

KODIAK COPPER CORP by KODIAK COPPER CORP.

Kodiak Copper Corp

Kodiak Energy Inc

Kodiak Gas Services Inc

fuboTV Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) shares are trading lower premarket on Tuesday.
On Monday, the company expressed disappointment over TelevisaUnivision&#8216;s decision to pull its programming, leaving thousands of Spanish-speaking consumers without access <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42663598/televisaunivision-pulls-spanish-language-programming-from-fubo-impacting-thousands-of-hispanic-con" rel="noreferrer noopener">to vital local news and weather</a>.
According to Fubo, the dispute arises from TelevisaUnivision demanding a 25% price increase and imposing unfair bundling practices that force subscribers to pay for channels they do not watch.
Additionally, Fubo criticized the separate subscription required for Vix+ to access all of TelevisaUnivision&#8217;s sports content.
The company said it remains open to fair negotiations with TelevisaUnivision and highlighted its ongoing dedication to the Hispanic community.
Fubo stated its commitment to offering premium content at competitive rates and emphasized its refusal to accept terms that would burden its subscribers or investors.
Fubo continues to provide a robust selection of Spanish-language programming through its Latino plan, featuring networks such as ESPN Deportes, FOX Deportes, Telemundo Acción, and beIN Sports Español, at what it claims is the lowest price among live TV streaming platforms.
Last week, FuboTV disclosed the launch of Hallmark+, which is available as a standalone premium subscription <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42601547/fubo-launches-hallmark-as-standalone-or-add-on-expanding-current-linear-partnership" rel="noreferrer noopener">or an add-on for Fubo customers</a>.
This launch builds on Fubo&#8217;s existing distribution agreement with Hallmark, which already includes Hallmark&#8217;s linear channels.
Investors can gain exposure to the stock via ProShares Metaverse ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VERS#NYSE">VERS</a>).
Price Action: At the last check on Tuesday, FUBO shares were trading lower by 1.46% at $1.35 premarket.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41685125/fubotv-q3-earnings-subscribers-grow-9-to-1-61-million-narrows-eps-loss-raises-annual-outlook" target="_blank" rel="noreferrer noopener">FuboTV Q3 Earnings: Subscribers Grow 9% To 1.61 Million, Narrows EPS Loss, Raises Annual Outlook</a></li>
</ul>
Photo: courtesy of FuboTv

Equities

News

Small Cap

Tech

FUBO

VERS

fuboTV Battles TelevisaUnivision for Fair Pricing In Spanish-Language Showdown

Warren Buffett&nbsp;is entering 2025 with the largest cash reserve at&nbsp;Berkshire Hathaway&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) in over three decades. 
What Happened:&nbsp;The conglomerate&#8217;s cash holdings have reached a staggering $325 billion, marking the highest percentage of total assets since 1990, CNBC<a href="https://www.cnbc.com/2024/12/22/buffett-heads-into-2025-with-biggest-cash-position-in-more-than-30-years.html"> reported</a> on Tuesday.
This cash accumulation comes as Buffett, 94, finds few attractive investment opportunities amid a highly valued market. The &#8220;Buffett indicator,&#8221; which compares&nbsp;the total market value of&nbsp;U.S. stocks to GDP, has soared to 209%, a level not seen since the 1929 market peak, according to Oppenheimer data.
Throughout 2024, Buffett sold significant portions of his largest holdings, including&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and&nbsp;Bank of America Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), offloading $133 billion in stocks during the year&#8217;s first three quarters. Despite this, Berkshire&#8217;s shares rose 27% in 2024, its best performance since 2021.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/12/42642371/smith-wessons-fate-hangs-in-the-balance-as-supreme-court-weighs-mexicos-gun-trafficking-lawsuit-swbi-stock-down-27-over-past-month-heres-whats-next?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Smith &amp; Wesson&#8217;s Fate Hangs In The Balance As Supreme Court Weighs Mexico&#8217;s Gun Trafficking Lawsuit: SWBI&nbsp;Stock Down 27% Over Past Month, Here&#8217;s What&#8217;s Next</a>
Buffett&#8217;s strategy may involve waiting for a major acquisition opportunity, potentially benefiting his successor,&nbsp;Greg Abel. Analyst&nbsp;Kevin Heal&nbsp;from Argus Research suggests that some of the cash could be used for investments in distressed situations, allowing successors to leave their mark.
"This will also provide an opportunity for the successors to make their own mark when Mr. Buffett ocially hands over the reins."
Why It Matters: This substantial cash reserve positions Berkshire Hathaway for strategic maneuvers in the coming years. Recently, Buffett&#8217;s investment activities have shown a shift. In December, Berkshire significantly increased its stake in <a href="https://www.benzinga.com/markets/equities/24/12/42666459/warren-buffett-once-called-berkshire-the-opposite-of-those-who-hurry-to-sell-now-hes-offloading-apple-and-snapping-up-occidental-petroleum-amid-a-20-drop">Occidental Petroleum Corp.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), acquiring approximately 8.9 million shares over a few days. This move, totaling around $405 million, raised Berkshire&#8217;s ownership to 28% of Occidental, valued at approximately $12 billion.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, BRK.A&#8217;s YTD returns rose by 25.69% while that of BRK.B increased by 25.35%
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42642808/americas-fatal-flaw-is-its-sharply-increasing-addiction-to-government-debt-says-expert-and-the-mother-of-all-bubbles-is-ready-to-pop?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">America&#8217;s &#8216;Fatal Flaw&#8217; Is Its &#8216;Sharply Increasing Addiction&#8217; To Government Debt, Says Expert And The &#8216;Mother Of All Bubbles&#8217; Is Ready To Pop</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Markets

General

AAPL

Warren Buffett Heads Into 2025 With $325 Billion Cash Pile, His Largest in Over Three Decades: Expert Says It 'Will Provide An Opportunity For The Successors To Make Their Own Mark'

From tree-lighting ceremonies, carol sing-alongs, to cute gifts, the Christmas spirit is alive and kicking, bringing families and communities together.
For cryptocurrency enthusiasts, the joy has doubled on the back of Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) record-breaking run leading up to the special day.
However, things were just the exact opposite during the Christmas of 2022.
What happened: After a searing bull market that catapulted Bitcoin and several other tokens to record highs in 2021, things took a drastic U-turn in 2022.&nbsp;
With implosions like the FTX (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ftt/usd">FTT</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42151412/bankrupt-crypto-exchange-ftx-to-commence-payments-to-customers-creditors-in-early-2025#:~:text=In%20October%2C%20a%20U.S.%20bankruptcy,over%20Robinhood%20shares%20in%20September.">exchange bankruptcy</a> and the collapse of the Terra (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/luna/usd">LUNA</a>) cryptocurrency, the market froze in the cryptocurrency winter of 2022.&nbsp;
Bitcoin fell to $16,000 at its lowest point, with a price on Christmas Day at&nbsp; $16,841.99.
See Also:<a href="https://www.benzinga.com/24/12/42640293/trump-congratulates-bitcoiners-on-new-all-time-highs-as-apex-crypto-suffers-first-weekly-loss-since-election-triumph">Trump Congratulates Bitcoin Community On New All-Time Highs Just As Top Crypto Suffers First Weekly Loss Since His Election Triumph</a>
However, if you were still an optimist and gifted your family $150 worth of Bitcoin on the festive day, you wouldn't have disappointed them in the least.
The market turned around dramatically in 2024, and fueled by Donald Trump's election victory, Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41575112/is-bitcoins-trump-trade-still-valid-its-complicated-but-watch-these-two-data-points">breached the $100,000 milestone</a>.
To set the record straight, Bitcoin traded at $94,140.23 as of this writing. This meant the stash you gifted on Christmas 2022 would be worth $838.44 today, representing a profit of 458%.
To put this in context, it was larger than the average amount an American is estimated to spend on gifts this holiday season, which is $641, <a href="https://nrf.com/media-center/press-releases/2024-holiday-spending-expected-reach-new-record">according </a>to the National Retail Federation.&nbsp;
So, basically, the 2022 gift would have increased your family&#8217;s purchasing power, allowing them to buy even more gifts for your loved ones in 2024.
However, everything is not lost if you ended up panic-selling your Bitcoin stash in 2022. If your belief in the asset&#8217;s long-term potential remains strong, you may wish to buy some this Christmas.
Price Action: At the time of writing, Bitcoin was exchanging hands at $94,140.23, down 0.71% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42640482/dogecoin-flips-into-the-green-as-trump-appoints-longtime-loyalist-katie-miller-to-join-the-department-of-government-efficiency">Dogecoin Turns Green As Trump Appoints Loyalist Katie Miller To The Department Of Government Efficiency</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$FTT

$LUNA

If You Gave Your Loved Ones A $150 Bitcoin Christmas Gift In 2022, It'd Be Worth More Than What An Average American Spends On The Holiday In 2024

Raymond James analyst Robert Majek initiates coverage on ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Outperform rating and announces Price Target of $1200.

Price Target

Initiation

Analyst Ratings

Raymond James Initiates Coverage On ServiceNow with Outperform Rating, Announces Price Target of $1200

On Monday, Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) secured several major defense contracts, solidifying its role as a key player in <a target="_blank" href="https://www.defense.gov/News/Contracts/Contract/Article/4016173/" rel="noreferrer noopener">U.S. military and allied operations</a>.
The company received a $3.37 billion modification to an existing agreement, expanding logistics support for the F-35 Lightning II Joint Strike Fighter program.
This initiative encompasses ground maintenance, pilot training, supply chain management, and depot activities for the Air Force, Marine Corps, Navy, Foreign Military Sales (FMS) customers, and other partners.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42658286/metas-ai-powered-ad-growth-and-expanding-user-base-drive-analyst-optimism" rel="noreferrer noopener">Meta User Base, AI-Powered Ad Growth Drive Analyst Optimism</a>
Work will occur in Texas, Florida, South Carolina, Georgia, and California, with completion anticipated by December 2025.
Lockheed Martin has also won a $335.7 million contract modification for the F-35 Joint Strike Fighter program. This deal supports various 2025 activities, including aircraft induction, field and depot site support, and specialized equipment procurement.
The funds come from multiple sources, including Navy and Air Force procurement budgets and contributions from FMS customers and program partners. Work will primarily occur in Fort Worth, Texas, and will likely conclude by the end of 2025.
The company&#8217;s Moorestown, New Jersey division secured a $10.5 million contract to continue engineering and development for the AEGIS Combat System.
The project, focusing on delivering advanced weapon system capabilities for the Navy&#8217;s FFG 62 program, will run until March 2025. Separately, Lockheed Martin&#8217;s Orlando, Florida unit received a $71.6 million contract to provide depot-level support for Apache attack helicopters, with an estimated completion date of December 2025.
Lockheed Martin stock gained 7% year-to-date. Elon Musk&#8217;s <a target="_blank" href="https://www.benzinga.com/news/24/12/42525698/as-elon-musk-takes-on-lockheed-martin-made-f-35s-experts-question-feasibility-of-replacing-manned-fighter-jets-with-drones" rel="noreferrer noopener">recent push for drone warfare</a> over traditional manned aircraft has sparked debate among experts regarding its feasibility.
Musk criticized Lockheed Martin&#8217;s F-35 stealth fighter program, advocating for the use of drone swarms, which he showcased in a video, and questioning the continued investment in piloted jets. Musk, a Donald Trump ally, is a co-lead of Trump&#8217;s Department of Government Efficiency (DOGE).
Goldman Sachs <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42468190/defense-stocks-face-headwinds-as-trumps-doge-targets-spending-cuts-goldman-sachs-downgrades-general-dynamics-to-sell" rel="noreferrer noopener">maintained a Sell rating</a> on Lockheed Martin, citing concerns about the F-35 program, which DOGE leadership has identified as a potential cost-cutting target.
Analyst Noah Poponak highlighted risks to margins and spending, noting that Lockheed&#8217;s free cash flow is projected to remain flat over the coming years. Poponak also pointed out the stock&#8217;s high valuation, trading at 23 times estimated 2025 earnings, which he considers a steep premium given these challenges.
Investors can gain exposure to Lockheed Martin through Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>) and iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>).
Price Action:&nbsp;LMT stock traded higher by 0.52% to $489.01 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42645821/elon-musks-xai-expands-with-new-chatbot-app" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s xAI To Expand With New Chatbot App</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Lockheed Martin Secures $3.37 Billion F-35 Contract And More

<a href="https://www.fly.faa.gov/adv/adv_otherdis.jsp?advn=17&amp;adv_date=12242024&amp;facId=DCC/DCC&amp;title=AAL+MAIN+AND+SUBS+GROUND+STOP&amp;titleDate=12/24/24" title="https://www.fly.faa.gov/adv/adv_otherdis.jsp?advn=17&amp;adv_date=12242024&amp;facId=DCC/DCC&amp;title=AAL+MAIN+AND+SUBS+GROUND+STOP&amp;titleDate=12/24/24">https://www.fly.faa.gov/adv/adv_otherdis.jsp?advn=17&amp;adv_date=12242024&amp;facId=DCC/DCC&amp;title=AAL+MAIN+AND+SUBS+GROUND+STOP&amp;titleDate=12/24/24</a>

FAA Issued Nationwide Groundstop For American Airlines Flights

AAL: -5% &#x7C; <a href="https://www.tipranks.com/news/the-fly/american-airlines-down-3-after-groundstop-notice-issued?utm_source=benzinga.com&amp;utm_medium=referral">American Airlines grounds all flights due to technical issues</a>
&nbsp;
CMND: 123% &#x7C; <a href="https://www.benzinga.com//node/42667676">Clearmind Medicine Secures IRB Approval For Alcohol Use Disorder Trial At Yale</a>
&nbsp;
CREV: 244% &#x7C; <a href="https://www.benzinga.com//node/42663154">Carbon Revolution Has Reached An Agreement With Orion Infrastructure Capital For A Further $25M Financing, Which Will Be Released In 5 Tranches, Each Equal To $5M</a>

Movers

Trading Ideas

CMND

CREV

Market-Moving News for December 24th

Raymond James analyst Tim Thein reinstates Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Outperform and announces $110 price target.

Raymond James Reinstates Outperform on Federal Signal, Announces $110 Price Target

The Russian government has announced a six-year ban <a href="https://www.benzinga.com/money/cryptocurrency-mining">on cryptocurrency mining</a> in ten regions, effective Jan. 1, 2025, citing concerns over excessive energy consumption.
The restrictions, set to last until March 15, 2031, will apply to both individual and pool mining operations, Tass <a href="https://tass.ru/ekonomika/22755633">reported</a>.
The ban targets Dagestan, Ingushetia, Kabardino-Balkaria, Karachay-Cherkessia, North Ossetia, Chechnya, and the occupied territories of Donetsk and Lugansk People&#8217;s Republics, as well as the Zaporizhia and Kherson regions. 
The Russian government also issued a temporary ban that restricts operations during peak demand in parts of Irkutsk Region, Buryatia, and the Zabaikalsky Krai between Nov. 15 and March 15, annually.
The move aims to address imbalances in energy consumption and costs. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42647516/bitcoins-2025-outlook-suddenly-looks-uncertain-heres-why">Bitcoin&#8217;s 2025 Outlook Suddenly Looks Uncertain: Here&#8217;s Why</a>
According to Sergey Kolobanov, deputy director of the Center for the Economy of Fuel and Energy Sectors, "The ban is connected not only with the local electricity shortage, but also with the benefits for paying for electricity in some regions." 
While Russia <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42244078/vladimir-putin-signs-bitcoin-mining-crypto-taxation-law">legalized mining last November</a>, provided that miners register with the Federal Tax Service, these new restrictions highlight the ongoing challenges of managing the energy consumption associated with cryptocurrency mining.
This decision comes three weeks after Russian president Vladimir Putin said that &#8220;nobody can ban Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), pointing out that cryptocurrencies will develop &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42317460/vladimir-putin-says-nobody-can-ban-bitcoin-stresses-crypto-will-develop-one-way-or-the-other">one way or the other</a>.&#8221; 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42647239/foresight-ventures-55m-investment-in-the-block-seeks-to-shape-the-future-of-crypto-media-forest-bai">Foresight Ventures&#8217; $55M Investment In The Block Seeks To Shape The Future Of Crypto Media: Forest Bai</a></li>
</ul>
Image: Shutterstock

Did Vladimir Putin Just Ban Bitcoin Mining In Russia? The Devil Is In The Details

Goldman Sachs analyst Gabriela Borges maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $372 to $415.

CRWD

Goldman Sachs Maintains Buy on CrowdStrike Holdings, Raises Price Target to $415

Brazilian authorities said on Monday that they have halted the construction of the plant that Chinese EV giant BYD Co Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is building in Salvador, Bahia after finding workers living and working in conditions analogous to &#8220;slavery.&#8221;
What Happened: Authorities ordered that the construction of the factory in Bahia be stopped after rescuing 163 people working at the site, according to a statement by the Labor Prosecutor&#8217;s Office (MPT).
The authorities shut down the workers&#8217; lodgings and communicated the same to both BYD and construction firm Jinjiang Construction Brazil Ltd, one of the contractors hired by the company to carry out the construction, it added.
MPT&#8217;s statement said that the workers lived in conditions analogous to slavery across four main lodgings. In one of the lodgings, the workers slept on beds without mattresses and 31 workers shared one bathroom, it said. 
At the construction site, there were only eight badly maintained chemical toilets for about 600 workers, it said, while also noting multiple accidents at the site. In one case, a worker suffered an accident after not having a break for 25 days.
The MPT also noted that the conditions constituted &#8220;forced labor.&#8221; If a worker were to terminate their employment contract after six months, they would leave the country without any pay for their work since the company deducted their airfare to and from Brazil, in addition to other costs, the statement said. 
BYD did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comment.
Why It Matters: BYD is China&#8217;s largest EV maker and makes plug-in hybrids and battery electric vehicles which are sold in China, Europe, and also Brazil. In November alone, the company made 540,588 new energy vehicles as compared to 316,510 in the corresponding month of 2023.
BYD <a href="https://www.benzinga.com/news/24/01/36839203/warren-buffett-backed-byd-sees-higher-profits-for-fy23-after-taking-over-tesla-as-biggest-ev-seller" target="_blank" rel="noreferrer noopener">took over Tesla</a>&nbsp;as the world's largest BEV seller in the fourth quarter of 2023. However, Tesla took back the crown in the first quarter of 2024 and has been holding on to it since.
For the third quarter between July and September, BYD reported operating revenue of&nbsp;<a href="https://www.benzinga.com/news/24/10/41647639/teslas-chinese-rival-byd-outshines-elon-musks-ev-giant-in-quarterly-revenue-for-first-time-since-202" target="_blank" rel="noreferrer noopener">201.12 billion yuan ($28.25 billion)</a> and net profit of 11.6 billion yuan. 
The company&#8217;s new factory in Bahia was expected to be operational by next year.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42666472/gms-60000-cadillac-lyriq-was-its-best-selling-ev-in-2024-as-of-q3-is-premium-the-way-to-go-for-ev-makers" target="_blank" rel="noreferrer noopener">GM's $60,000 Cadillac Lyriq Was Its Best Selling EV In 2024 As Of Q3: Is Premium The Way To Go For EV Makers?</a></li>
</ul>
Photo courtesy: Shutterstock

Global

BYDDY

Brazil Authorities Halt Work At BYD Factory Site After Workers Found In 'Slavery' Like Conditions

Allurion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company's common stock, par value $0.0001 per share (the "Common Stock").
The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 3, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis on The New York Stock Exchange ("NYSE") as of the opening of trading on January 3, 2025. The CUSIP number of 02008G 201 will be assigned to the Company's Common Stock when the reverse stock split becomes effective.
When the reverse stock split becomes effective, every twenty five (25) of the Company's issued shares of Common Stock will be combined into one (1) issued share of Common Stock, without any change to the par value per share. This will reduce the number of outstanding shares of Common Stock from approximately 67,781,585 million shares to approximately 2,711,263 million shares.

Stock Split

ALUR

Allurion Technologies Announces 1-for-25 Reverse Stock Split Effective January 3

D. Boral Capital analyst Jason Kolbert initiates coverage on AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy rating and announces Price Target of $25.

RCEL

D. Boral Capital Initiates Coverage On AVITA Medical with Buy Rating, Announces Price Target of $25

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54170813&amp;newsitemid=20241224565771&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=c412227958438d701e3e355f86717b04">Enanta Pharmaceuticals, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts ("the Court") has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 ("the '953 Patent") in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid&#x2122; (nirmatrelvir tablets; ritonavir tablets).
The Court issued a summary judgment decision granting Pfizer's motion that the ‘953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.

Legal

ENTA

Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned

Webuy Global Ltd (NASDAQ:<a href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) (the "Company") is pleased to announce the remarkable success of its recent Disney cruise campaign, powered by its revolutionary Micky1.0 Travel AI on WhatsApp. By seamlessly integrating advanced AI technology with personalized customer service, Webuy demonstrated its ability to drive significant customer engagement and financial results.
 AI-Driven Success &nbsp;
The Disney cruise campaign leveraged Webuy's digital marketing expertise to direct leads to Micky1.0, the Company's AI-powered travel assistant. Micky1.0 efficiently answered customer inquiries, provided real-time quotes, and tailored recommendations, before transferring qualified leads to travel consultants for deal closure. This streamlined process highlights the synergy between advanced technology and human expertise.
 Outstanding Results &nbsp;
From December 10th to 23rd,2024,&nbsp; the Disney campaign exclusively drove the following financial achievements: • &nbsp; &nbsp;Receivable Booking Value (RBV): SGD 465,527 • &nbsp; &nbsp;Booking Revenue: SGD 162,202 These figures highlight the significant impact of the Disney project, powered by Webuy's AI capabilities, on revenue growth. &nbsp;

WBUY

Webuy Global Achieves Revenue Milestone With AI-Driven Disney Cruise Campaign

Ratings for Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.21, a high estimate of $26.00, and a low estimate of $14.50. This current average has increased by 4.32% from the previous average price target of $21.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1735041643_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Nordstrom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$14.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nordstrom. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Nordstrom compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Nordstrom's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nordstrom's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JWN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nordstrom analyst ratings.</a>
<h2>Delving into Nordstrom's Background</h2>
Nordstrom is a fashion retailer that operates about 93 department stores and 280 off-price Nordstrom Rack stores. The company also operates both full- and off-price e-commerce sites, two clearance stores, and six Local locations. Nordstrom's largest merchandise categories are women's apparel (27% of 2023 sales), shoes (26% of 2023 sales), men's apparel (15% of 2023 sales), and beauty (13% of 2023 sales). Nordstrom, which traces its history to a shoe store opened in Seattle in 1901, continues to be partially owned and managed by members of the eponymous family.
<h3>Nordstrom's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Nordstrom's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 4.34%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Nordstrom's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 1.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nordstrom's ROE stands out, surpassing industry averages. With an impressive ROE of 4.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Nordstrom's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.51%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Nordstrom's debt-to-equity ratio surpasses industry norms, standing at 4.37. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Nordstrom

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.67, a high estimate of $27.00, and a low estimate of $18.00. This current average has decreased by 10.93% from the previous average price target of $24.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1735041636_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Enanta Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enanta Pharma. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Enanta Pharma compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Enanta Pharma's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Enanta Pharma's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Enanta Pharma Better</h2>
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>Financial Insights: Enanta Pharma</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately -22.84% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Enanta Pharma's net margin excels beyond industry benchmarks, reaching -197.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Enanta Pharma's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -20.76%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Enanta Pharma's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.43%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.43, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Throughout the last three months, 4 analysts have evaluated Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Glimpse Group, revealing an average target of $3.66, a high estimate of $4.67, and a low estimate of $2.65. This upward trend is apparent, with the current average reflecting a 16.19% increase from the previous average price target of $3.15.
<img src="https://www.benzinga.com/files/images/story/2024/1735041629_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Glimpse Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.67</td>
<td>$4.67</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>Westlake Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.67</td>
<td>$2.65</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.65</td>
<td>$2.65</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.65</td>
<td>$2.65</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Glimpse Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Glimpse Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Glimpse Group's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRAR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glimpse Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Glimpse Group Better</h2>
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
<h3>Unraveling the Financial Story of Glimpse Group</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Glimpse Group's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -21.47%. This indicates a decrease in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Glimpse Group's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -41.59%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glimpse Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -9.04%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.6%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Glimpse Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRAR

Glimpse Group Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $2.88, along with a high estimate of $4.00 and a low estimate of $2.50. Observing a 21.01% increase, the current average has risen from the previous average price target of $2.38. 
<img src="https://www.benzinga.com/files/images/story/2024/1735041620_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive FlexShopper is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Michael Diana</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to FlexShopper. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FlexShopper compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of FlexShopper's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into FlexShopper's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FPAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on FlexShopper analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About FlexShopper</h2>
FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers. Its products include electronics, computers, furniture, mattresses, cameras and camcorders, audio, musical instruments, health, fitness and sports, video games, homes, gardens and tools, appliances, and vacuums on a payment, lease basis. The firm generates a majority of its revenue by leasing its products. The company enables consumers utilizing its e-commerce marketplace to shop for brand-name electronics, home furnishings, and other durable goods on a lease-to-own (LTO) basis.
<h3>Breaking Down FlexShopper's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining FlexShopper's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 22.95% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 20.37%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): FlexShopper's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.66%, the company showcases efficient use of assets and strong financial health.
Debt Management: FlexShopper's debt-to-equity ratio is notably higher than the industry average. With a ratio of 21.36, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FPAY

The Analyst Verdict: FlexShopper In The Eyes Of 4 Experts

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).
The trial will be led at Yale School of Medicine's Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind's FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100.

Clearmind Medicine Secures IRB Approval For Alcohol Use Disorder Trial At Yale

Barclays raised the firm's price target on Kodiak Sciences (KOD) to $4 from $3 and keeps an Underweight rating on the shares. The firm says the com...

Kodiak Sciences price target raised to $4 from $3 at Barclays

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on Kodiak Sciences (KOD – Research Report). The associated price targ...

Cautious Approach: Kodiak Sciences' Retinal Pipeline Progress and Hold Rating

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

As previously reported, Jefferies upgraded Kodiak Sciences (KOD) to Buy from Hold with a price target of $20, up from $6. With three positive Phase...

Jefferies upgrades 'major turnaround play' Kodiak Sciences to Buy

Kodiak stock rallies 32% after Jefferies upgrades to buy

The company states: "Nona Biosciences announced a collaboration with Kodiak Sciences (KOD). This partnership aims to advance the discovery of novel...

Kodiak Sciences, Nona Biosciences partner on next-gen antibody therapies

Nona Biosciences, Kodiak Sciences partner on antibody therapies for ophthalmic diseases

Nona Biosciences announced a collaboration with Kodiak Sciences (KOD). This partnership aims to advance the discovery of novel multi-target antibod...

Kodiak Sciences, Nona Biosciences to collaborate on antibody therapies

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Tracking Baker Brothers Portfolio - Q3 2024 Update

ABCL

ACAD

AGIO

ALGS

ALKS

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BMEA

CERS

CMRX

DNLI

EWTX

GLUE

HOOK

IGMS

IMCR

IMTX

INCY

INSM

IPHA

IPHYF

KALA

KNSA

KYMR

MCRB

MDGL

NRIX

RARE

REGN

REPL

RVMD

RYTM

SGMT

SMMT

STOK

TCRX

TRDA

TSVT

VTVT

Press Releases

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Earnings

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Kodiak Sciences to Present at Innovate Retina 2024

Kodiak Sciences to Participate in Upcoming Investor Conferences

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Contracts

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

Comments

Kodiak Sciences

ニュース

最新ニュース Kodiak Sciences (NASDAQ:KOD) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル